FDA Grants Approval for Diphenhydramine Hydrochloride ANDA219470
The FDA's approval of a generic version of Diphenhydramine Hydrochloride by Annora Pharma introduces a new competitor in the antihistamine market. This could disrupt pricing and market share for established brands, necessitating strategic adjustments.
Company
Annora Pharma
Asset
FDA
Indication
Allergy / Antihistamine
Status
Approved
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The FDA's approval of a generic version of Diphenhydramine Hydrochloride by Annora Pharma introduces a new competitor in the antihistamine market. This could disrupt pricing and market share for established brands, necessitating strategic adjustments.
Why it matters
The FDA's approval of a generic version of Diphenhydramine Hydrochloride by Annora Pharma introduces a new competitor in the antihistamine market. This could disrupt pricing and market share for established brands, necessitating strategic adjustments.
What changed
Regulatory Approval
Analysis
The FDA has granted approval for ANDA219470, a generic version of Diphenhydramine Hydrochloride by Annora Pharma.
The FDA's approval of a generic version of Diphenhydramine Hydrochloride by Annora Pharma introduces a new competitor in the antihistamine market. This could disrupt pricing and market share for established brands, necessitating strategic adjustments.
Monitor market entry timelines and pricing strategies from Annora Pharma and competitors.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.